∙ 1\. Age: 18 years ≤ Age ≤ 75 years, female patient. 2. Patients with cervical neuroendocrine carcinoma confirmed by histopathology or cytology (if mixed type carcinoma, the composition of neuroendocrine carcinoma is\>60%), whose FIGO stage is stage I-II, and who can be operated according to the gynecological examination of an experienced Chief physician.

∙ 3\. According to the RECIST 1.1 standard, patients have at least one measurable diameter target lesion (tumor lesion CT scan length ≥ 10mm, lymph node lesion CT scan short diameter ≥ 15mm, scan layer thickness 5mm).

∙ 4\. ECOG PS 0-1 points. 5. The estimated postoperative survival time is greater than 3 months. 6. The main organs function normally and meet the following standards:

• The blood routine test must meet the following criteria: (no blood transfusion within 14 days)

‣ HB ≥ 100g/L

⁃ WBC ≥ 3 × 109/L

⁃ ANC ≥ 1.5 × 109/L

⁃ PLT ≥ 100 × 109/L

• Biochemical examination must meet the following standards:

‣ BIL\<1.5 times upper limit of normal value (ULN)

⁃ ALT and AST\<2.5ULN, GPT ≤ 1.5 × ULN

⁃ Serum Cr ≤ 1ULN, endogenous creatinine clearance rate\>60ml/min (Cockcroft Goult formula).

‣ 7\. Not participating in other clinical studies before and during treatment.

‣ 8\. Women of childbearing age must undergo a serum pregnancy study within 7 days before the first medication use, and the results should be negative. Female participants of childbearing age and male participants with partners of childbearing age must agree to contraception within 24 weeks after signing the informed consent form and the last administration of the study medication.

‣ 9\. The subjects voluntarily joined this study, signed an informed consent form, had good compliance, and cooperated with follow-up.